New Medication for Osteoarthritis Knee Pain

Trial Objective

The purpose of this trial is to determine if a new FDA-approved medication called  Hymovis™ is effective in reducing or eliminating pain in people with osteoarthritis in their knee. The medication will be injected into the participant’s knee using a pneumatic  external compression device called KneeTap™ guided by ultrasound. This study will determine how the knee joint fluid proteins react to this medication to help reduce cartilage loss and joint pain.

New Medication for Osteoarthritis Knee Pain

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, contact Mary Gill at 303.398.1473, or complete the form below.

Who Can Participate

Patients who have an x-ray confirming mild to moderate osteoarthritis in the knee. Participants must not have had a knee infection or knee surgery within 12 months or a cortisone injection within 3 months of starting the study. Participants must be able to walk six minutes without a cane or walker.


Estimated Time Commitment

5 visits over 12 months

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

Fidia

Age

21-80


Gender

Any Gender

Principal Investigators

Co-Investigators


Request More Information

*
*
*
*